Now Reading
FDA clears sEEG electrode technology for neurological disorders

FDA clears sEEG electrode technology for neurological disorders

The Evo sEEG electrode represents the company’s second FDA 510(k) cleared product, providing a full line of electrode technology to address an estimated worldwide market of $100 million for patients requiring diagnostic brain mapping procedures. 

As opposed to cortical electrodes, sEEG electrodes provide a similar function at the subsurface level of the brain by using a less invasive process as it does not require removal of the top portion of the patient’s skull. It has become the predominant technology used in these procedures due to its less invasive placement and subsurface location. 

The company’s Evo Cortical and sEEG Electrodes are a portfolio of thin-film electrodes. Potential advantages include increased signal clarity and reduced noise; better tactile feedback during insertion into brain tissue; and faster order fulfillment due to an automated manufacturing process.

As previously reported, NeuroOne is also advancing a pipeline of therapeutic electrode technologies for brain tissue ablation and chronic stimulation use for DBS (deep brain stimulation) and spinal cord stimulation for chronic back pain. These therapeutic electrode technologies represent addressable markets between $500 million and $6 billion.

Dave Rosa, CEO of NeuroOne, said: “This represents yet another critical milestone met by the Company as we continue to execute our strategy. The next steps for the company are to expand the sEEG labeling for longer-term use, which we believe will be a key part of our commercialization strategy for the Evo sEEG electrode, and complete the development of an sEEG ablation electrode/probe for the ablation of brain tissue and permanently implanted stimulation electrodes for patients with chronic applications such as epilepsy, Parkinson’s disease, and chronic back pain.” 

See Also
Clinicy integrates cloud computing to reach the last people in the line

As previously reported, the company expects to be launch-ready by the end of the calendar year 2021, pending additional regulatory clearance of sEEG labeling for longer-term use.

(Except for the headline, this story has not been edited by The Technology Express staff and is published from a syndicated feed)


© 2024 The Technology Express. All Rights Reserved.

Scroll To Top